Rubin, D. T. Et Al. 2022. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. The Lancet Gastroenterology and Hepatology , vol.7, no.1 , 17-27.

Rubin, D. T., Dotan, I., DuVall, A., Bouhnik, Y., Radford-Smith, G., Mishkin, D. S., ... Arrisi, P.(2022). Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. The Lancet Gastroenterology and Hepatology , vol.7, no.1, 17-27.

Rubin, David Et Al. "Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials," The Lancet Gastroenterology and Hepatology , vol.7, no.1, 17-27, 2022

Rubin, David T. Et Al. "Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials." The Lancet Gastroenterology and Hepatology , vol.7, no.1, pp.17-27, 2022

Rubin, D. T. Et Al. (2022) . "Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials." The Lancet Gastroenterology and Hepatology , vol.7, no.1, pp.17-27.

@article{article, author={David T Rubin Et Al. }, title={Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials}, journal={The Lancet Gastroenterology and Hepatology}, year=2022, pages={17-27} }